|
1
|
Weycker D, Edelsberg J, Kartashov A,
Barron R and Lyman G: Risk and healthcare costs of
chemotherapy-induced neutropenic complications in women with
metastatic breast cancer. Chemotherapy. 58:8–18. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
DeSantis C, Ma J, Bryan L and Jemal A:
Breast cancer statistics, 2013. CA Cancer J Clin. 64:52–62. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Raftopoulou M and Hall A: Cell migration:
Rho GTPases lead the way. Dev Biol. 265:23–32. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hoppe R, Achinger-Kawecka J, Winter S,
Fritz P, Lo WY, Schroth W and Brauch H: Increased expression of
miR-126 and miR-10a predict prolonged relapse-free time of primary
oestrogen receptor-positive breast cancer following tamoxifen
treatment. Eur J Cancer. 49:3598–3608. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jordan VC and O'Malley BW: Selective
estrogen-receptor modulators and antihormonal resistance in breast
cancer. J Clin Oncol. 25:5815–5824. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Moerkens M, Zhang Y, Wester L, van de
Water B and Meerman JH: Epidermal growth factor receptor signalling
in human breast cancer cells operates parallel to estrogen receptor
α signalling and results in tamoxifen insensitive proliferation.
BMC Cancer. 14:2832014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lorizio W, Wu AH, Beattie MS, Rugo H, Tchu
S, Kerlikowske K and Ziv E: Clinical and biomarker predictors of
side effects from tamoxifen. Breast Cancer Res Treat.
132:1107–1118. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yeh WL, Lin HY, Wu HM and Chen DR:
Combination treatment of tamoxifen with risperidone in breast
cancer. PLoS One. 9:e988052014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cuzick J, Powles T, Veronesi U, Forbes J,
Edwards R, Ashley S and Boyle P: Overview of the main outcomes in
breast-cancer prevention trials. Lancet. 361:296–300. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hendrick A and Subramanian VP: Tamoxifen
and thromboembolism. JAMA. 243:514–515. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang G, Nowsheen S, Aziz K and Georgakilas
AG: Toxicity and adverse effects of Tamoxifen and other
anti-estrogen drugs. Pharmacol Ther. 139:392–404. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
El-Ashmawy NE and Khalil RM: A review on
the role of L-carnitine in the management of tamoxifen side effects
in treated women with breast cancer. Tumour Biol. 35:2845–2855.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Suddek GM: Protective role of thymoquinone
against liver damage induced by tamoxifen in female rats. Can J
Physiol Pharmacol. 92:640–644. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Perou CM, Sørlie T, Eisen MB, van de Rijn
M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA,
et al: Molecular portraits of human breast tumours. Nature.
406:747–752. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Goldhirsch A, Wood WC, Coates AS, Gelber
RD, Thürlimann B and Senn HJ: Panel members: Strategies for
subtypes - dealing with the diversity of breast cancer: Highlights
of the St. Gallen International Expert Consensus on the Primary
Therapy of Early Breast Cancer 2011. Ann Oncol. 22:1736–1747. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Howell A, Cuzick J, Baum M, Buzdar A,
Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY and
Tobias JS: ATAC Trialists' Group: Results of the ATAC (Arimidex,
Tamoxifen, Alone or in Combination) trial after completion of 5
years' adjuvant treatment for breast cancer. Lancet. 365:60–62.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mauri D, Pavlidis N, Polyzos NP and
Ioannidis JP: Survival with aromatase inhibitors and inactivators
versus standard hormonal therapy in advanced breast cancer:
Meta-analysis. J Natl Cancer Inst. 98:1285–1291. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tamoxifen for early breast cancer: An
overview of the randomised trials. Early Breast Cancer Trialists'
Collaborative Group. Lancet. 351:1451–1467. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cuzick J, Forbes JF, Sestak I, Cawthorn S,
Hamed H, Holli K and Howell A: International Breast Cancer
Intervention Study I Investigators: Long-term results of tamoxifen
prophylaxis for breast cancer-96-month follow-up of the randomized
IBIS-I trial. J Natl Cancer Inst. 99:272–282. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lee MH, Kim JW, Kim JH, Kang KS, Kong G
and Lee MO: Gene expression profiling of murine hepatic steatosis
induced by tamoxifen. Toxicol Lett. 199:416–424. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Murata Y, Ogawa Y, Saibara T, Nishioka A,
Fujiwara Y, Fukumoto M, Inomata T, Enzan H, Onishi S and Yoshida S:
Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in
adjuvant tamoxifen for breast cancer patients. Oncol Rep.
7:1299–1304. 2000.PubMed/NCBI
|
|
23
|
Labbe G, Pessayre D and Fromenty B:
Drug-induced liver injury through mitochondrial dysfunction:
Mechanisms and detection during preclinical safety studies. Fundam
Clin Pharmacol. 22:335–353. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Carthew P, Martin EA, White IN, De Matteis
F, Edwards RE, Dorman BM, Heydon RT and Smith LL: Tamoxifen induces
short-term cumulative DNA damage and liver tumors in rats:
Promotion by phenobarbital. Cancer Res. 55:544–547. 1995.PubMed/NCBI
|
|
25
|
White IN, de Matteis F, Davies A, Smith
LL, Crofton-Sleigh C, Venitt S, Hewer A and Phillips DH: Genotoxic
potential of tamoxifen and analogues in female Fischer F344/n rats,
DBA/2 and C57BL/6 mice and in human MCL-5 cells. Carcinogenesis.
13:2197–2203. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
El-Beshbishy HA: Hepatoprotective effect
of green tea (Camellia sinensis) extract against
tamoxifen-induced liver injury in rats. J Biochem Mol Biol.
38:563–570. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
El-Beshbishy HA: The effect of dimethyl
dimethoxy biphenyl dicarboxylate (DDB) against tamoxifen-induced
liver injury in rats: DDB use is curative or protective. J Biochem
Mol Biol. 38:300–306. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Vince AR, Hayes MA, Jefferson BJ and
Stalker MJ: Hepatic injury correlates with apoptosis, regeneration,
and nitric oxide synthase expression in canine chronic liver
disease. Vet Pathol. 51:932–945. 2014. View Article : Google Scholar : PubMed/NCBI
|
